OUTLINE: This is a multi-center study.
PHASE I:
- UGT1A1 *28 7/7 genotype IS NOT present
- Cetuximab 250 mg/m2 IV days 1, 8, and 15
- Irinotecan 125 mg/m2 IV days 1 and 8
- RAD001 PO QD (dose determined at the time of registration; subjects will remain at this dose level until treatment